RxDoctor Payments Data

Landis Barnes, DO

Internal Medicine · Brooklyn, NYNPI 1447263090

Payments from drug & device makers

$969in general payments, 2019–2025

Across 48 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Idorsia Pharmaceuticals US Inc$812
  • Scpharmaceuticals Inc.$47
  • EMD Serono, Inc.$42
  • Gilead$28
  • Smith+Nephew$21
  • Orexo US, Inc.$18

What the payments were for

  • Food & beverage$969100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$969 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$40,600
Medicare patients
62
Services billed
355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala63$233,621
TriumeqAbacavir/Dolutegravir/Lamivudi52$184,180
TivicayDolutegravir Sodium78$164,499
JulucaDolutegravir/Rilpivirine36$119,256
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf19$81,665
PrezcobixDarunavir/Cobicistat33$74,297
DescovyEmtricitabine/Tenofov Alafenam34$68,519
GenvoyaElviteg/Cob/Emtri/Tenof Alafen16$59,733
OdefseyEmtricitab/Rilpiviri/Tenof Ala13$40,738
IsentressRaltegravir Potassium17$33,082
JanuviaSitagliptin Phosphate59$30,713
Atovaquone55$22,172
EliquisApixaban41$21,124
PifeltroDoravirine11$19,095
Lopinavir-RitonavirLopinavir/Ritonavir12$8,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$28$361,874113 claims
Smith+NephewSantyl$21$4,10515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →